"Dr. Mekan brings a combined 18 years of experience in hematology and oncology across academic research, clinical practice ...

In a Q&A with Jeff Casberg, MS, RPh, senior vice president of clinical pharmacy services at IPD Analytics, Casberg explains ...

Ultragenyx's strong revenue growth, diverse streams, and late-stage pipeline make it a standout in rare disease and gene ...

During a recent panel discussion sponsored by Purdue University, industry leaders explain how the technology is revolutionizing drug development and production ...

This is the first CSCO Guidelines recommendation for lisaftoclax (APG-2575), making it the only China-developed Bcl-2 ...

Immunome's strong financial position supports ongoing clinical development and potential market entry for key assets. See why ...

Zhejiang Jingxin Pharmaceutical won approval for the drug in China in 2023 ... and confirmed “we will not be in clinical development.” The pipeline pullback could see Evotec’s R&D spending ...

A record nearly 30% of US-listed small- and mid-cap biotech companies are trading at or below cash, suggesting the market does not ascribe any value to their existing business or drug development ...

suggesting the market does not ascribe any value to their existing business or drug development pipeline, according to Jefferies analysts. "The sector needs a predictable, science-led regulator to ...

The biotech is developing an experimental drug for the most common of a family of disorders all caused by errors in ...